Phase 1 CLL Clinical Trials
13 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–13 of 13 trials
Recruiting
Phase 1
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)
Nurix Therapeutics, Inc.572 enrolled62 locationsNCT05131022
Recruiting
Phase 1Phase 2
Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
T-lymphoblastic LymphomaRelapsed/Refractory B-cell Acute Lymphoblastic LeukemiaRelapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL+3 more
Beijing Biotech96 enrolled1 locationNCT07523555
Recruiting
Phase 1
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)Waldenstrom Macroglobulinemia (WM)+2 more
Nurix Therapeutics, Inc.248 enrolled16 locationsNCT04830137
Recruiting
Phase 1Phase 2
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAcute Leukemia+8 more
Ossium Health, Inc.12 enrolled9 locationsNCT05589896
Recruiting
Phase 1
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
Diffuse Large B Cell LymphomaMantle Cell LymphomaFollicular Lymphoma+4 more
Newave Pharmaceutical Inc60 enrolled4 locationsNCT04775745
Recruiting
Phase 1
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
Lymphoma, B-CellChronic Lymphocytic Leukemia (CLL)Lymphoma, Non-Hodgkin (NHL)+1 more
Umoja Biopharma106 enrolled8 locationsNCT06528301
Recruiting
Phase 1
Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma
Refractory LymphomaRelapsed CLLRefractory CLL
Paolo Caimi, MD18 enrolled1 locationNCT06916767
Recruiting
Phase 1
A Phase I Dose Finding Study of MB-CART2219.1
LymphomaCLLAcute Lymphoblastic Leukemia, Pediatric
University Hospital Tuebingen36 enrolled2 locationsNCT07108868
Recruiting
Phase 1Phase 2
A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies
Chronic Lymphocytic Leukemia (CLL)High Grade B-Cell Lymphoma, Not Otherwise SpecifiedMultiple Myeloma (MM)+3 more
IDP Discovery Pharma S.L.37 enrolled11 locationsNCT05908409
Recruiting
Phase 1
Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL
CLL/SLL
Ascentage Pharma Group Inc.144 enrolled9 locationsNCT04215809
Recruiting
Phase 1Phase 2
Safety and Efficacy of KLS-1 Monotherapy in Malignant Neoplasms
Solid Tumor, AdultCLL
Vector Vitale LLC36 enrolled1 locationNCT06506643
Recruiting
Phase 1Phase 2
Allogeneic CARCIK-CD19 in Adults/Pediatric B-cell NHL or Chronic Lymphocytic Leukemia
CLLB-cell NHL
Fondazione Matilde Tettamanti Menotti De Marchi Onlus29 enrolled1 locationNCT05869279
Recruiting
Phase 1Phase 2
Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL
CLL/SLL
Stichting Hemato-Oncologie voor Volwassenen Nederland112 enrolled24 locationsNCT05791409